Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin

BACKGROUND: Oral semaglutide was approved in 2019 for blood glucose control in patients with type 2 diabetes mellitus (T2DM) and was the first oral glucagon-like peptide 1 receptor agonist (GLP-1 RA). T2DM is associated with substantial healthcare expenditures in the US, so the cost of a new interve...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Pharmacoeconomics
Main Authors: Wehler, Elizabeth, Lautsch, Dominik, Kowal, Stacey, Davies, Glenn, Briggs, Andrew, Li, Qianyi, Rajpathak, Swapnil, Alsumali, Adnan
Format: Artigo
Sprog:Inglês
Udgivet: Springer International Publishing 2020
Fag:
Original Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7882575/
https://ncbi.nlm.nih.gov/pubmed/33150566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-020-00967-7
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker